NewLake Capital Partners (NLCP) is a $300M-market-cap cannabis REIT with 30 triple-net properties leased to MSOs. The Q1 2026 call (May 8, 2026) is the first since medical cannabis rescheduling completed in April 2026. Two disclosures matter: the chairman explicitly compared NLCP's OTC status to IIPR's NYSE listing — 22% P/E gap on identical business — and the CEO said MSOs accumulated ≈$1.4B in uncertain tax positions over the last two years instead of paying 280E. Both are quantifiable for the first time. Neither is priced.

What the filing says

Rescheduling now partial reality. Medical cannabis rescheduling to Schedule III formally completed in April 2026 (DOJ order). NLCP introduced a new disclosure metric: 50-55% of annualized base rent is now derived from federally-legal medical activities. Adult-use rescheduling hearings begin late June 2026, conclude July, with final DEA rule "months, maybe a couple of quarters" later — implying Q4 2026 or Q1 2027 publication. A November 2026 ban on synthetic THC / hemp-derived intoxicants adds a separate tailwind by removing unregulated competition from licensed-operator markets.

The 280E mechanism is not what consensus assumes. CEO Anthony Coniglio: "Over the last two years, the medical operators were not utilizing cash flow to pay the 280E portion of their taxes. They were accumulating that liability in their uncertain tax position line item on the balance sheet." This reframes rescheduling from operator margin uplift to balance-sheet cleanup.

Cross-ticker confirmation in Q1 2026 10-Qs:

Aggregate $1.4B accumulated UTP across four challenging MSOs. If IRS or Treasury grants retroactive relief, balance sheets clean in one quarter. If prospective-only, UTPs remain but tenants get small forward tax savings (small because they were already retaining the cash).

Listing asymmetry now articulable. Chairman Gordon DuGan: "There is already at least one REIT listed on the New York Stock Exchange that does exactly what we do... I've never really gotten a fully cogent answer as to why that's listed and we're not." Coniglio confirmed NLCP meets all listing requirements except cannabis illegality. On the same earnings cycle, IIPR CEO Paul Smithers confirmed uplisting is not part of the DEA rescheduling action — pure exchange discretion. NLCP and IIPR operate the same business with the same top tenants (Curaleaf, Trulieve, Cresco) and trade at a 22% P/E discount on the OTC name. NLCP is the only OTC cannabis REIT publicly articulating an uplisting path.

Tenant management actively addressed Q4 worry list. Three Q1 credit enhancements: Wellgreens retenanted Cannabist's San Diego dispensary; Holistic Industries added as guarantor on Acreage Pennsylvania cultivation; Canopy USA added as guarantor on Acreage Massachusetts. In Q4 2025, DuGan had flagged Cannabist and Acreage as the two worry tenants — both addressed in one quarter.

Cannabist remains live. ≈8% ABR across 4 properties (IL + MA, dispensary + cultivation) — current on rent through May 2026. Security deposits ≈1 month per property versus the 6-month standard. Cannabist filed CCAA in Canada in Q1 2026; on the same date IIPR declared default on Cannabist + Battle Green (≈5% IIPR ABR). The asymmetric pay status — current to NLCP, defaulted to IIPR — appears strategic: NLCP's IL/MA assets are what Cannabist needs intact for going-concern sale.

Q1 financials. AFFO $0.48/share (vs $0.51 Q4 2025), payout ratio 90% at the high end of the 80-90% target. Three vacant cultivation properties drive the drag. Balance sheet: 1.6% LTV, 72x debt service coverage, $7.6M total debt, no maturities until May 2027.

What the market thinks

NLCP: $14.41, 11.53x P/E, 11.86% yield, OTC, RVOL 0.05x (dollar volume ≈$700K-$1.5M/day, accumulation in size is operationally hard). IIPR: $55.55, 14.17x P/E, 13.45% yield, NYSE-listed since 2016.

Authored scenarios across cannabis-rescheduling (loading 0.4), cannabis-debt-maturity-wall (0.4), cannabis-utp-accumulation (0.3), plus dividend carry yield probability-weighted state prices:

Forward fair value: $17-18 over 12 months, against $14.41 spot. Reverse-implied probabilities from the current price suggest the market is weighting ≈50% on bearish states (reversal or extended delay) and assigning near-zero probability to a 2027 uplisting application. That distribution is harder to defend after the April 2026 rescheduling completion and the chairman's IIPR framing.

Why the gap exists

• OTC venue blocks institutional accumulation. Most cannabis-focused funds cannot hold NLCP. Pricing reflects retail and yield buyers, not analytical institutions.
• The $1.4B UTP pattern is not synthesized publicly. Each MSO 10-Q discloses UTPs separately; aggregating requires reading five filings and noting GTBIF as the cohort outlier.
• DuGan's IIPR comparison and Smithers's same-cycle confirmation that uplisting is exchange-discretionary have not been connected — they live in separate transcripts.
• AFFO drift Q4 $0.51 → Q1 $0.48 reads as deterioration. It is vacancy timing on three cultivation properties; re-leasing one removes the drag.

Risks ranked by impact

1. Dividend cut. 90% payout at high end of target; if AFFO drift continues, 100% breach → cut → -25-30% one-day move on REIT yield-name dynamics. Hard exit trigger.
2. Adult-use rescheduling delayed or reversed. Authored scenarios assign ≈10% to reversal, ≈30% to delay past 2027. Compounds time decay on uplisting optionality.
3. Cannabist defaults on NLCP. 1-month deposit protection vs 6-month standard. Currently paying; asymmetric vs IIPR.
4. IRS challenges existing UTP positions. Tail risk — would crash MSO credit and bleed into tenant rent collection.
5. Uplisting denied by exchange discretion. Thesis collapses to carry plus sector beta. Smithers's comment is a reminder that the listing call is not regulatory.

Catalysts

• June-July 2026: DEA adult-use hearings
• August 2026: NLCP Q2 earnings — Cannabist update, vacancy progress, dividend safety
• Sep-Oct 2026: Cannabist IL/MA buyer announcements
• November 2026: NLCP Q3 earnings (critical interim checkpoint); hemp ban executes
• Q4 2026 / Q1 2027: DEA final rule on adult-use rescheduling
• Year-end 2026: IRS retroactive 280E guidance window
• Mid-2027: NLCP uplisting application 8-K — re-rate would be priced in a single session

What would change our mind

Bullish: NLCP files uplisting application; second MSO releases UTP > $50M in a single quarter (corroborates retroactive path); Cannabist IL/MA transitions to a quality buyer with NLCP rent intact; vacancy filled on any of PA/NV/MA cultivation.

Bearish: Dividend cut or softening guidance; DEA blocks or materially delays adult-use; second Cannabist-style default on a NLCP tenant; IRS challenges existing UTP positions; AFFO drifts below $0.45.

Evidence

Memo LR: 1.4.